Abstract: The present application provides a compound dry powder inhalant, comprising baicalin, ambroxol hydrochloride, L-leucine and phosphate, wherein based on a mass of the compound dry powder inhalant, L-leucine accounts for 0-50%, phosphate accounts for 15-35%, and a total mass of baicalin and ambroxol hydrochloride accounts for 15-85%, and wherein a mass ratio of baicalin to ambroxol hydrochloride is 1:0.2 to 2. The compound dry powder inhalant has a Dv90?5 ?m. The drug combination of baicalin and ambroxol hydrochloride can effectively reduce inflammation and oxidative damage in lung tissue, alleviate pulmonary edema and histopathological changes, and reduce pulmonary dysfunction and pulmonary fibrosis.

Abstract: Foliamngiferosides having the general formula (I) are disclosed, wherein R is H or —OCH. The preparation method of the compounds, pharmaceutical compositions comprising the compounds as the active ingredients, the use of the compounds and the pharmaceutical compositions for inhibiting the activity of ?-glucosidase are also disclosed. The foliamangiferosides can be used in preparing drugs for treating diabetes.

Abstract: Use of chemical ingredients in Cynomorium as phytoestrogen is provided by the present invention. Particularly, use of Cynomorium, extracts of Cynomorium, or at least one ingredient chosen from chrysophanol, emodin, catechin, (?)-epicatechin-3-O-gallate, naringenin-4?-O-glucopyranoside, and phlorizin, in manufacturing medicaments for treating and/or preventing diseases related to insufficient of estrogen secretion in mammal (for example, human), or use in manufacturing medicaments used as phytoestrogens is provided by the present invention. The extracts of Cynomorium, compositions containing extracts of Cynomorium or active ingredients thereof, and methods of treating and/or preventing diseases related to insufficient of estrogen secretion are also provided by the present invention.